Safety and feasibility of chemotherapy followed by liver transplantation for patients with definitely unresectable colorectal liver metastases: insights from the TransMet randomised clinical trial.

Fiche publication

Date publication

juin 2024

Journal

EClinicalMedicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr HEYD Bruno

Tous les auteurs :
Adam R, Badrudin D, Chiche L, Bucur P, Scatton O, Granger V, Ducreux M, Cillo U, Cauchy F, Lesurtel M, Mabrut JY, Verslype C, Coubeau L, Hardwigsen J, Boleslawski E, Muscari F, Jeddou H, Pezet D, Heyd B, Lucidi V, Geboes K, Lerut J, Majno P, Grimaldi L, Boukhedouni N, Piedvache C, Gelli M, Levi F, Lewin M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38721015

Résumé

Despite the increasing efficacy of chemotherapy (C), the 5-year survival rate for patients with unresectable colorectal liver metastases (CLM) remains around 10%. Liver transplantation (LT) might offer a curative approach for patients with liver-only disease, yet its superior efficacy compared to C alone remains to be demonstrated.